ArriVent BioPharma, Inc. AVBP
ArriVent BioPharma, Inc. (Nasdaq: AVBP) is an oncology drug developer. Its lead program, firmonertinib, is in Phase 3 for first-line EGFR exon 20 insertion NSCLC (FURVENT) and PACC-mutant NSCLC (ALPACCA). Its next catalyst on record is ARR-002: First patient dosed in Phase 1 trial (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ARR-002 — First patient dosed in Phase 1 trial (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| firmonertinib (FURVENT) | 1L EGFR exon 20 insertion NSCLC | small molecule | Phase 3 |
| firmonertinib (ALPACCA) | 1L EGFR PACC-mutant NSCLC | small molecule | Phase 3 |
| ARR-217 (MRG007) | unresectable locally advanced or metastatic solid tumors | antibody | Phase 1 |
| ARR-002 | ovarian and endometrial cancers / solid tumors (MUC16/NaPi2b ADC) | antibody | Pre-clinical |
Recent results and decisions
- Oct 19, 2026positive ArriVent announces Cancer Cell publication of FURTHER Phase 1b results showing firmonertinib achieved 43% (160 mg) and 68% (240 mg) confirmed overall response rate in treatment-naïve EGFR PACC-mutant NSCLC.
43% (160 mg) and 68% (240 mg) confirmed overall response rate (ORR), with 11.1- and 16.0-months median progression free survival (PFS), both by blinded independent central review (BICR), respectively in front-line EGFR PACC-mutant NSCLC.
Filing - Oct 19, 2026n/a ArriVent continues to enroll patients in global Phase 3 ALPACCA trial evaluating firmonertinib versus osimertinib or afatinib in first-line EGFR PACC-mutant NSCLC.
We continue to enroll patients in our global Phase 3 ALPACCA trial as we seek to address this area of high unmet medical need where there is no current standard of care.
Filing - Oct 6, 2026missed Phase 3 FURVENT missed primary endpoint of BICR PFS: 240mg 11.0 vs 9.5 months control (HR 0.75, p=0.0654); 160mg 8.4 months (HR 0.91); investigator-assessed PFS HR 0.61 for 240mg.
today announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of prog
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.